Liver study tests drug safety for patients with impaired function
NCT ID NCT04271488
Summary
This study aims to understand how mild to moderate liver problems affect how the body processes an experimental drug called tasurgratinib. Researchers will compare drug levels in 18 participants—some with liver impairment and some healthy—after a single dose. The goal is to gather safety information to guide future dosing for people with liver conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Eisai Trial Site #1
RECRUITINGMintato-ku, Tokyo, Japan
-
Eisai Trial Site #2
RECRUITINGYuhu, Oita Prefecture, Japan
-
Eisai Trial Site #3
RECRUITINGBukyo-ku, Tokyo, Japan
-
Eisai Trial Site #4
TERMINATEDKurume, Fukuoka, Japan
-
Eisai Trial Site #5
RECRUITINGKofu, Yamanashi, Japan
-
Eisai Trial Site #6
RECRUITINGHakata, Fukuoka, Japan
-
Eisai Trial Site #7
RECRUITINGKyoto, Japan
-
Eisai Trial Site #8
RECRUITINGShinjuku-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.